This module presented by Dr Shaun Fleming, provides an overview of the current guideline treatments for adult Acute Lymphoblastic Leukaemia, as well as recognising the roles of targeted therapies and immunotherapies, and patient risks to guide treatment decisions for patients with ALL.
Acute Lymphoblastic Leukaemia in Adults
AUS
$0
free
Certificate of Completion
1 hr
Expired
1 Credits
Course Description
Course Details
Expiry Date: 2021-03-31
Professions: Specialist
Faculty
Dr Shaun Fleming
MBBS (Hons), FRACP, FRCPA
Clinical and Laboratory Haematologist
Alfred Health & Northern Health, Melbourne, VIC
Accreditation
The curriculum is endorsed by the RACP/RCPA Committee for Joint College training in Haematology (CJCT) and the Haematology Society of Australia and New Zealand (HSANZ). Fellows of the RACP may claim CPD hours under the CPD Program (CPDP).
Learning Objective(s)
At the end of this module, you will be better able to:
- Describe the
current guideline-recommended treatment regimens for adult ALL, including
paediatric-inspired regimens, and their survival outcomes - Recognise the
varying roles of current targeted therapies and immunotherapies in
different subtypes of adult ALL - Identify the
factors associated with prognostication in adult ALL - Explain how measurable residual disease and new genomic risk
grouping helps to classify patient risk and guide treatment decisions in
ALL